Clinical Trials Browser

Interventional × Neoplasms × anlotinib × Clear all

NCT06456138 2024-06-13

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Phase 1/2 Not yet recruiting

Neoplasms

NCT03736837 2021-03-15

ALTER-L004

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT04566952 2020-10-30

ANLOLA

Phase 2 Unknown

Carcinoma, Ovarian Epithelial, Adnexal Diseases, Carcinoma, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms, Urogenital Neoplasms

NCT01878448 2019-05-22

ALTN/STS

Phase 2 Completed

Neoplasms

NCT01874873 2019-05-21

ALTN/MTC

Phase 2 Completed

Neoplasms

NCT02388919 2017-09-18

ALTER0303

Phase 2/3 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT02752516 2017-09-18

A Phase I Additional Study of Anlotinib on Tolerance and Pharmacokinetics

Phase 1 Unknown

Neoplasms

NCT01924195 2015-10-28

Phase II Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0302）

Phase 2 Completed

Carcinoma, Non-Small-Cell Lung, Neoplasms